One Fusion Pharmaceuticals Insider Raised Stake By 370% In Previous Year
Viewing insider transactions for Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
View our latest analysis for Fusion Pharmaceuticals
The Last 12 Months Of Insider Transactions At Fusion Pharmaceuticals
Over the last year, we can see that the biggest insider purchase was by Independent Director Steven Gannon for US$90k worth of shares, at about US$2.03 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$4.39. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does Fusion Pharmaceuticals Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From looking at our data, insiders own US$2.1m worth of Fusion Pharmaceuticals stock, about 0.7% of the company. I generally like to see higher levels of ownership.
So What Do The Fusion Pharmaceuticals Insider Transactions Indicate?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Fusion Pharmaceuticals stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Fusion Pharmaceuticals. Case in point: We've spotted 4 warning signs for Fusion Pharmaceuticals you should be aware of, and 3 of them can't be ignored.
Of course Fusion Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
